---
schema_version: "secwatch.filing_event.v1"
accession: "0000920148-25-000021"
form_type: "8-K"
ticker: "LH"
cik: "0000920148"
company_name: "LABCORP HOLDINGS INC."
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T02:14:05.732242+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Labcorp Q4 revenue $3.33B (+9.8% YoY); adj. EPS $3.45; FY2025 rev. midpoint ~$14.0B, adj. EPS $16.00

## Summary
- Q4 revenue $3.33B (+9.8% YoY); diluted EPS $1.70 vs ($1.95); adjusted EPS $3.45 vs $3.30; free cash flow $665.1M vs $412.4M.
- Full year 2024 revenue $13.01B (+7.0%); diluted EPS $8.84 vs $4.33; adjusted EPS $14.57 vs $13.56; free cash flow $1.10B vs $748.7M.
- Diagnostics Labs segment Q4 revenue $2.59B (+10.2%); Biopharma Lab Services revenue $767.0M (+10.4%).
- FY2025 guidance: revenue $13.88B-$14.05B (midpoint +7.4%), adjusted EPS $15.60-$16.40 (midpoint +9.8%), free cash flow $1.10B-$1.25B.
- Board declared $0.72 quarterly dividend payable March 12, 2025; $839M spent on acquisitions in 2024.

## SEC filing metadata
- accession: 0000920148-25-000021
- form_type: 8-K
- ticker: LH
- cik: 0000920148
- company_name: LABCORP HOLDINGS INC.
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/920148/000092014825000021/0000920148-25-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/920148/000092014825000021/lh-20250206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000920148-25-000021
- JSON: https://secwatch.observer/filing/0000920148-25-000021.json
- Plain text: https://secwatch.observer/filing/0000920148-25-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.